WO2017116355A1 - Échafaudage tissulaire à biocompatibilité et propriétés mécaniques améliorées et son procédé de fabrication - Google Patents

Échafaudage tissulaire à biocompatibilité et propriétés mécaniques améliorées et son procédé de fabrication Download PDF

Info

Publication number
WO2017116355A1
WO2017116355A1 PCT/TR2016/050506 TR2016050506W WO2017116355A1 WO 2017116355 A1 WO2017116355 A1 WO 2017116355A1 TR 2016050506 W TR2016050506 W TR 2016050506W WO 2017116355 A1 WO2017116355 A1 WO 2017116355A1
Authority
WO
WIPO (PCT)
Prior art keywords
pcl
tissue
chitosan
solution
hours
Prior art date
Application number
PCT/TR2016/050506
Other languages
English (en)
Inventor
Hilal TURKOGLU SASMAZEL
Original Assignee
Atilim Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atilim Universitesi filed Critical Atilim Universitesi
Publication of WO2017116355A1 publication Critical patent/WO2017116355A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges

Definitions

  • the present invention relates to a new tissue scaffold production method using a natural polymer, chitosan and polycaprolactone which is a synthetic biocompatible polymer that can be used for the treatment of tissue losses occurring due to various reasons in the human body.
  • the cell strom made of the cells with the same purpose, aggregated to construct a specific function, which come together to constitute the organs is called a tissue.
  • Tissue losses may occur during the surgeries performed for the treatment of various injuries and illnesses. In cases where these losses are not recovered, problems such as loss of function and/or aesthetic defects that affect human health and living standards arise.
  • the tissues are capable of self-renewal, but there is a limit of this capability. There are two important elements for the self- renewal of the tissues. The first of these is the requirement to be in contact with neighboring cells by means of bio-signals. The other important element is the requirement of adsorption for the growth of animal cells. In cases where there is a considerable loss of tissue and the said two important elements are lacking and/or insufficient, tissue regeneration cannot occur .
  • the body provides self-healing without outside intervention, in cases when tissue loss is below the limit values. In case the loss of tissue is above the limit values, external support is absolutely needed. In cases when the tissue losses are above the limit value, the method of transferring pieces taken from a region of the patient's body with a similar tissue or from a region of another species with a genetically similar tissue, to the damaged area, is widely used. During the treatment, in cases when pieces taken from a region of the patient's body with a similar tissue are used, a new injured area is formed on the patient's body because of a second surgery, thus causing a prolonged healing process, as well as a loss of function and/or aesthetic defects at the region where tissue is taken.
  • tissue compatibility problems may arise. Due to such tissue compatibility problems, it becomes more difficult to find a donor. There is also a risk of tissue transplant rejection although there is biocompatibility . In the event of transferring the lost tissue from another living body, different problems may be faced. There is a possibility that the tissue taken from a different species may be pathogenic, i.e. carrying disease. Despite the fact that animals used for tissue transplantation were raised specifically to have genetics close to human genetics, there is a possibility of tissue transplant rejection for this transplant too.
  • tissue scaffold biomaterials resembling the extracellular matrix structure in natural human tissue, which is called the tissue scaffold have started to be used.
  • Tissue scaffolds are placed in the lost tissue area to provide the structural basis necessary for enabling the adsorption and reproduction of the cells to rebuild the missing tissue.
  • the selection of the material is the most important criterion. Materials must be biocompatible, in other words it should not lead to adverse tissue reactions when implanted in the body and must also have a surface chemistry that enhances cell adsorption and function. Biodegradability is another desired feature. However during degradation, the material should not lose its biocompatibility, rendering toxic products and must have mechanical properties that will provide the appropriate environment for the new tissue. Furthermore, it should have a porous structure that allows passage of cells and nutrients. Among materials with these features, polymers, ceramics, metals and combinations of them can be considered.
  • biodegradable natural polymers such as alginate, gelatin, starch, collagen, chitin and chitosan, as well as biodegradable synthetic polymers such as polycaprolactone, polylactic-co-glycolic acid, polyethylene glycols, polyvinyl alcohol and polyurethane are used.
  • Natural polymers are preferred as they are bioactive/biofunctional and biologically and chemically similar to natural tissues.
  • biomaterials made of natural polymers such as collagen and chitin, have poor mechanical resistance and generally cannot be melted by heat and often a special solvent is required.
  • the synthetic polymers used in the field of tissue engineering have such advantages as that they can be easily processed, unlike the natural polymers, that they are degradable by means of chemical hydrolysis and that the degree of their degradation does not change from one patient to the other as they are not affected, by enzymatic processes. While a limited number of manufacturing techniques such as freeze drying in aqueous solution/crosslinking are used to produce tissue scaffolds from natural polymers, numerous techniques such as solvent casting, particle removal, phase separations, electrospinning are used to produce tissue scaffolds from synthetic polymers.
  • the electrospinning technology has been developed in the last decade, for tissue engineering applications to manufacture biodegradable and/or biocompatible filamentary structures with a fiber diameter of micrometer or nanometer size.
  • the polymer solution is directed along the capillary in such a manner that a polymer droplet is formed at the head/end section.
  • High voltage is applied to a section between the end portion and the grounded collection zone. If the electric field tension is greater than the surface tension of the droplet, the fountain of polymer solution is accelerated towards the collection zone. As the fountain proceeds in the air, the solvent moves away from the structure and a non-woven fabric structure is formed in the collection zone.
  • the grounded rotary cylinder may be used as the collection zone.
  • non-woven fibrous structures for tissue engineering purposes by using natural macromolecules such as collagen and fibrinogen and synthetic polymers as polycaprolactone, polyglycolic acid, polylactic-co-glycolic acid, and synthetic polypeptides.
  • natural macromolecules such as collagen and fibrinogen and synthetic polymers as polycaprolactone, polyglycolic acid, polylactic-co-glycolic acid, and synthetic polypeptides.
  • tissue scaffold applications In practice natural polymers are preferred for tissue scaffold applications, due to their bioactive/biofunctional properties.
  • biodegradable synthetic polymers with the disadvantage that they cannot be obtained from natural sources, are preferred, as they can easily be processed and unlike the natural polymers, are degradable by chemical hydrolysis and they have advantages of their rate of degradation being able to change from one patient to other as they are affected by enzymatic processes.
  • Such features of the tissue scaffold as having the similar physical structure as the three dimensional structure of the living tissue, providing mechanical characteristics that are suitable to the region it is used and having a porous structure to allow a material exchange, may vary depending on the technique used for production.
  • tissue scaffolds obtained in a single stage do not show sufficient mechanical strength and flexibility.
  • Chitosan being one of the natural polymers, has such advantages as being cheaper and the second most abundant, thus easily obtainable natural polymer as it is obtained by deacetylation of chitin and as it is positively charged being able to interact with the glycosaminoglycans existing in the ECM, being biocompatible, having anti-microbial activity, being soluble in weak acids, can be easily processed as a film and porous tissue scaffold.
  • Chitosan films are quite fragile when wet.
  • PCL being a synthetic polymer
  • PCL can be processed easily because of its low melting temperature. Its mechanical properties and non-enzymatic degradability (decomposition through hydrolysis) can be regulated by PCL's crystalline structure.
  • PCL has such disadvantages as its limited bioactivity, being hydrophobic and uncharged, having sensitivity to via bacteria-degradability .
  • tissue scaffold obtained by dissolving simultaneously polycaprolactone and chitosan in acetic acid is described in application No. CN201310327715.
  • the poration process of the tissue scaffold is achieved by the creation of air gaps by suspending polycaprolactone-chitosan polymer in water and drying it under vacuum.
  • Tissue scaffold is obtained by integrating polycaprolactone with chitosan in a single phase using methane sulfonic acid as the reactive solvent, amino as a preservative agent and chitosan as the initiator.
  • polycaprolactone and chitosan are integrated as a separate layer by using a process of high pressure static spinning on the polylactic acid layer.
  • Polycaprolactone, and chitosan are mixed and spun under high pressure statically.
  • the tissue scaffold is obtained by using acetic acid as a solvent and dissolving chitosan and polycaprolactone at the same time.
  • the porous structure is obtained by adding a NaOH solution and drying it.
  • the application No. KR20060014449 discloses a method of culturing the fibroblast and keratinocyte cells together.
  • the improvement of a tissue scaffold material by using a plurality of different polymers also including chitosan and polycaprolactone, has been disclosed .
  • WO2006CN01027 discloses the production of nano-sized scaffolds by using the self-assembly approach, wherein numerous polymers including polycaprolactone and chitosan, as well as a plurality of anionic or cationic charges also including chitosan, are used.
  • polyelectrolyte solution is used together with the polymer solution to form a core-shell structure and these two solutions are used in the electrospinning process after being mixed at a certain ratio, to provide a single solution.
  • the application No. CN101653624 discloses the production of a fibrous structure obtained by preparing 3 polymers including PCL and chitosan as a single solution and applying it onto a rotating roller to apply electro-spinning.
  • the polymers are used as a single solution, often by being dissolved with a common solvent or dissolved separately and then mixed together.
  • the polymers used for this kind of approach are mixed together homogeneously, their physical and chemical properties cannot be sufficiently reflected in the final product.
  • the scaffolds should be biocompatible, should not be rejected by the immune system, should have a physical structure similar to the extracellular matrix, should show sufficient mechanical strength and flexibility, should remain in place until the tissue repair process begins and as the tissue takes shape, disappear not to create any toxic substances. It is seen that the biomaterials known in the prior art do not appear to offer all of these conditions.
  • tissue scaffolds with a good mechanical resistance and higher biocompatibility/bioactivity thanks to the chitosan/PCL hybrid structure, have been obtained.
  • the electrospinning technique has been selected as the production technique and the 3-dimensional (3D), similar to natural ECM, produced by this method provided high-density cell growth/migration in 3-dimensional (3D), non-woven reticulated structures .
  • the aim of the invention is to develop a new tissue scaffold suitable for use in the treatment of tissue losses with a critical flaw size, which is biocompatible, that is not rejected by the body, having chemical and biological activity, not generating any toxic substance, having sufficient mechanical strength and flexibility, with sufficiently porous structure for the diffusion of nutrients to enable the growth/reproduction of cells, and its manufacturing process.
  • Another object of the invention is to develop a tissue scaffold that is superior in terms of mechanism and porosity, due to the structure obtained by the solvent cast-freeze drying methods, wherein a natural polymer chitosan and a synthetic polymer, polycaprolactone are used in the composite structure.
  • Another object of the invention is to obtain a tissue scaffold having a good mechanical strength, obtained by eliminating its poor physical property which is the disadvantage of chitosan.
  • Figure 1 Scanning Electron Microscopy-SEM images obtained by scanning at 20 micrometers ( ⁇ ) scanning size, of the material freeze dried for 12 hours after pre-dried in the refrigerator at -20°C for 24 hours.
  • Figure 2 Scanning Electron Microscopy-SEM images obtained by scanning using 5 micrometers ( ⁇ ) scanning size, of the material freeze dried for 12 hours after pre-dried in the refrigerator at -20°C for 24 hours.
  • Figure 3 SEM images obtained by scanning using 20 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the refrigerator at -20°C for 24 hours.
  • Figure 4 SEM images obtained by scanning using 5 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the refrigerator at -20°C for 24 hours.
  • Figure 5 SEM images obtained by scanning using 20 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the refrigerator at -20°C for 48 hours.
  • Figure 6 SEM images obtained by scanning using 5 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the refrigerator at -20°C for 48 hours.
  • Figure 7 SEM images obtained by scanning using 20 ⁇ scanning size, of the material freeze dried for 12 hours after pre-dried in the incubator at 40°C for 5 hours.
  • Figure 8 SEM images obtained by scanning using 5 ⁇ scanning size, of the material freeze dried for 12 hours after pre-dried in the incubator at 40°C for 5 hours.
  • Figure 9 SEM images obtained by scanning using 20 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the incubator at 40°C for 5 hours
  • Figure 10 SEM images obtained by scanning using 5 ⁇ scanning size, of the material freeze dried for 24 hours after pre-dried in the incubator at 40°C for 5 hours
  • Figure 11 SEM images obtained by scanning using 20 ⁇ scanning size, of the material freeze dried for 48 hours after pre-dried in the incubator at 40°C for 5 hours
  • Figure 12 SEM images obtained by scanning using 5 ⁇ scanning size, of the material freeze dried for 48 hours after pre-dried in the incubator at 40°C for 5 hours
  • the present invention relates to a tissue scaffold which has a good biocompatibility and can degrade without causing toxic effects, that has a physical structure similar to the three- dimensional structure of the living tissue, which can provide mechanical properties suitable to the region used and which has a porous structure to allow the exchange of substances, and it also relates to its graduated production process.
  • the production process for the tissue scaffold that feature macro/micro-sized spherical porosity and a structure consisting of fibers in-between the same, presenting adequate mechanical strength and flexibility, having a composite PCL/chitosan material structure comprises of two stages, namely three- dimensional integration of the PCL fibrous structure with chitosan polymer and drying at the oven followed by freeze- drying.
  • first of all the structure consisting of PCL fibers known in the prior art should be achieved.
  • Achieving a structure consisting of PCL fibers comprises of the process steps set forth hereunder;
  • the three dimensional integration is achieved after obtaining a fibrous structure consisting of randomly oriented PCL fibers at thickness in the range of 0,1-2,5 mm for the tissue scaffolding that feature developed composite PCL/chitosan material structure of the invention and is freeze-dried after being dried in an oven .
  • the three-dimensional integration of the PCL fibrous structure with chitosan polymer comprises of the process steps set forth hereunder;
  • the resulting PCL/chitosan structure is the tissue scaffold obtained in a similar manner to the extracellular matrix (ECM) which performs the functions of natural scaffold in animal tissues .
  • ECM extracellular matrix
  • the poly ( ⁇ -caprolactone ) (PCL) being one of the synthetic polymers used in the first stage of the above-described production process, is a hydrophobic, biodegradable aliphatic polyester and has a vitric transition temperature of -60°C and a melting point at 60°C.
  • PCL is generally prepared by ring-opening polymerization of ⁇ - caprolactone . It is used as substrate for biodegradability studies and as matrix for controlled drug emission systems. As the degradation of the PCL in an in vivo medium is slower than that of poly ( -hydroxy acid), its use as a long-term, up to 1-2 years, controlled release device is more preferred. PCL is widely used in such areas as artificial skin production (in plain film) with tissue engineering, coating of urethral stents, musculoskeletal tissue engineering applications and most importantly, as a support material, i.e. tissue scaffold for osteoblast and fibroblast cell growth.
  • Chitosan (poly [ ⁇ - ( 1 , 4 ) -2-amino-2-deoxy-D-glucose ] ) , used in the second stage of the above-described production process and is one of the natural polymers, can be obtained as the result of the partial deacetylation of chitin.
  • Chitosan is a linear polysaccharide. It has a high potential for tissue engineering applications both because it contains chemically modifiable reactive amino and hydroxyl groups and it is easy to be physically manipulated for various pore structures. Chitosan is located in the exoskeletons of crustaceans and in the cell walls of fungi and is located in the cell wall is composed of different numbers of randomly located N-acetyl- glucosamine and D-glucosamine residues. Therefore it shares similar characteristics as glycosaminoglycan and hyaluronic acid found in articulation cartilage.
  • chitosan such as being biologically renewable; biodegradable, biocompatible, non-antigenic, nontoxic and bio-functional properties of it allow the use of this polymer and complexes obtained using it in biomedical applications such as wound dressing material, drug delivery systems.
  • Chitosan can be dissolved in weak acids and, consequently, a cationic polymer having a high charge density. Because of this property, chitosan can form polyelectrolyte complexes with numerous anionic polymers. Its degradation by lysozyme in the body provides the formation of macrophage activating oligomers. Fragmentation contributes to the healing of the wound tissue by providing the formation of N- acetylglucosamine, an important component of the dermal tissues. Moreover, it is also used as means of non-viral gene transport because of its ability to form complexes with DNA. Particularly it is preferred for bone tissue engineering studies, because of its osteo-compatibility and osteo-inductivity properties.
  • a tissue scaffold is obtained by providing a three-dimensional integration of the PCL fibrous structure with chitosan polymer.
  • the biocompatibility and biodegradability properties of the chitosan/PCL hybrid tissue scaffold formed by chitosan, a biodegradable natural polymer and PCL, a biodegradable synthetic polymer vary depending on the components used during production.
  • the inventive tissue scaffold with enhanced biocompatibility and mechanical properties is used in such a manner that the natural polymer chitosan and the synthetic polymer with a good biocompatibility polycaprolactone, form a composite structure.
  • tissue scaffold as having a physical structure similar to the three dimensional structure of the living tissue will allow to providing mechanical characteristics suitable to those of the region used and having a porous structure to allow material exchange, may vary depending on the technique used for production. While a limited number of manufacturing techniques using natural polymers, such as freeze- drying in aqueous solution/crosslinking for the production of tissue scaffolds, for the production of the same but using synthetic polymers numerous methods, such as solvent casting, particulate removal, phase separation, electrospinning are used.
  • the use of PCL tissue scaffolds produced by freeze-drying technique, in the Chondrocyte cell cultures is one of the tissue engineering applications that draw attention.
  • PCL fibers are produced by electrospinning technique for use in soft tissue engineering applications.
  • chitosan/PCL hybrid tissue scaffolds are fabricated using chitosan, a biodegradable natural polymer which is often preferred for the production of tissue scaffolds and a biodegradable synthetic polymer PCL.
  • Chitosan has many advantages, namely being cheaper, can be obtained by deacetylation of chitin which is the second most abundant natural polymer and is easily obtained, being positively charged able to provide interaction with negatively charged glycosaminoglycans in the ECM, being biocompatible, its anti-microbial activity, is soluble in weak acid, can be easily processed as film and porous tissue scaffold.
  • having very little flexibility in terms of mechanical properties occur and biodegradability limits are among the most important disadvantages.
  • the technique of electrospinning has been selected as the production technique and a high-density cell growth/migration is provided in 3- dimensional (3D), nonwoven reticulated structures that are similar to natural ECM, produced by this method.
  • the tissue scaffolds according to the present invention are achieved by a three-stage production process. Contact angle measurements are made for the characterization of the tissue scaffold obtained by using the inventive method and the results of the measurement are shown in Table 1.
  • the values shown below the title R + F are the contact angles obtained according to the freeze-drying time after pre-drying for 24 hours in the refrigerator at -20°C.
  • the values shown under the title I + F are the contact angles obtained according to the freeze- drying time after pre-drying in the incubator at 40°C for 5 hours .
  • tissue scaffold with enhanced biocompatibility and mechanical properties and its production method As the subject of the invention is a tissue scaffold with enhanced biocompatibility and mechanical properties and its production method; a tissue scaffold being biocompatible, with a physical structure similar to the three-dimensional structure of the live tissue, having a high mechanical strength, with a porous structure that enables the material exchange, providing an alternative treatment to the autograft, allograft and xenograft tissue transport and also eliminating some undesired negative aspects of this method and a tissue scaffold production method can be used in the treatment of tissue loss, the critical flaw size and has superior properties as compared to other similar products and methods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un échafaudage tissulaire biodégradable et composite qui présente une forte résistance mécanique et qui est destiné à être utilisé dans le traitement de pertes tissulaires à dimensions de défaut importantes, qui présente également une structure poreuse permettant un échange matériel et physique similaires in vivo, en une structure tridimensionnelle, obtenue au moyen d'un polymère naturel, du chitosane et du polycaprolactone qui est un polymère synthétique dans un procédé de fabrication en trois étapes, et son procédé de fabrication.
PCT/TR2016/050506 2015-12-29 2016-12-16 Échafaudage tissulaire à biocompatibilité et propriétés mécaniques améliorées et son procédé de fabrication WO2017116355A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2015/17198 2015-12-29
TR201517198 2015-12-29

Publications (1)

Publication Number Publication Date
WO2017116355A1 true WO2017116355A1 (fr) 2017-07-06

Family

ID=57851316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2016/050506 WO2017116355A1 (fr) 2015-12-29 2016-12-16 Échafaudage tissulaire à biocompatibilité et propriétés mécaniques améliorées et son procédé de fabrication

Country Status (1)

Country Link
WO (1) WO2017116355A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588912A (zh) * 2020-06-10 2020-08-28 四川大学 一种用于骨组织再生的多功能纤维膜及其制备方法
CN112107728A (zh) * 2020-09-01 2020-12-22 广东工业大学 一种负载抗菌肽β-HBD-3的PCL/Zif-8组织工程支架材料及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015712A (zh) 2007-02-26 2007-08-15 福建师范大学 聚己内酯—壳聚糖网络/羟基磷灰石复合多孔支架材料的制备方法
KR20070082114A (ko) 2006-02-15 2007-08-21 주식회사 엠씨티티 생체적합성 스캐폴드에서 섬유아세포와 피부각질세포를공동 배양하는 방법
WO2007124622A1 (fr) 2006-04-28 2007-11-08 Wuhan University Of Technology Échafaudage stratifié poreux en 3d utilisé en ingénierie tissulaire et procédé de préparation de celui-ci
US20090252798A1 (en) * 2006-10-06 2009-10-08 Trans Tissue Technologies Gmbh Matrix-gel graft without cells
CN101653624A (zh) 2009-09-18 2010-02-24 福建师范大学 复合纳米纤维小直径血管组织工程支架材料的制备方法
CN101704906A (zh) 2009-11-25 2010-05-12 华东师范大学 一步合成壳聚糖接枝聚己内酯阳离子共聚物的方法及其应用
CN102605466A (zh) 2012-03-02 2012-07-25 北京化工大学 一种天然聚电解质基核壳结构纳米纤维制备方法
CN103127554A (zh) 2013-03-05 2013-06-05 青岛大学 一种用于皮肤组织工程的纳米纤维双层支架制备方法
CN103418028A (zh) 2013-07-31 2013-12-04 苏州纳埃净化科技有限公司 一种多孔支架材料的制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070082114A (ko) 2006-02-15 2007-08-21 주식회사 엠씨티티 생체적합성 스캐폴드에서 섬유아세포와 피부각질세포를공동 배양하는 방법
WO2007124622A1 (fr) 2006-04-28 2007-11-08 Wuhan University Of Technology Échafaudage stratifié poreux en 3d utilisé en ingénierie tissulaire et procédé de préparation de celui-ci
US20090252798A1 (en) * 2006-10-06 2009-10-08 Trans Tissue Technologies Gmbh Matrix-gel graft without cells
CN101015712A (zh) 2007-02-26 2007-08-15 福建师范大学 聚己内酯—壳聚糖网络/羟基磷灰石复合多孔支架材料的制备方法
CN101653624A (zh) 2009-09-18 2010-02-24 福建师范大学 复合纳米纤维小直径血管组织工程支架材料的制备方法
CN101704906A (zh) 2009-11-25 2010-05-12 华东师范大学 一步合成壳聚糖接枝聚己内酯阳离子共聚物的方法及其应用
CN102605466A (zh) 2012-03-02 2012-07-25 北京化工大学 一种天然聚电解质基核壳结构纳米纤维制备方法
CN103127554A (zh) 2013-03-05 2013-06-05 青岛大学 一种用于皮肤组织工程的纳米纤维双层支架制备方法
CN103418028A (zh) 2013-07-31 2013-12-04 苏州纳埃净化科技有限公司 一种多孔支架材料的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANIMESH AGRAWAL ET AL: "Smooth Muscle Cell Alignment and Phenotype Control by Melt Spun Polycaprolactone Fibers for Seeding of Tissue Engineered Blood Vessels", INTERNATIONAL JOURNAL OF BIOMATERIALS, vol. 2015, 1 January 2015 (2015-01-01), pages 1 - 8, XP055358340, ISSN: 1687-8787, DOI: 10.1155/2015/434876 *
ANONYMOUS: "Chitosan-hyaluronic acid hydrogel coated poly(caprolactone) multiscale bilayer scaffold for ligament regeneration", CHEMICAL ENGINEERING JOURNAL, 15 January 2015 (2015-01-15), pages 478 - 485, XP055358255, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S1385894714011711> [retrieved on 20170323] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588912A (zh) * 2020-06-10 2020-08-28 四川大学 一种用于骨组织再生的多功能纤维膜及其制备方法
CN112107728A (zh) * 2020-09-01 2020-12-22 广东工业大学 一种负载抗菌肽β-HBD-3的PCL/Zif-8组织工程支架材料及其制备方法

Similar Documents

Publication Publication Date Title
Wu et al. Resorbable polymer electrospun nanofibers: History, shapes and application for tissue engineering
Khandan et al. Hydrogels: Types, structure, properties, and applications
Schiffman et al. A review: electrospinning of biopolymer nanofibers and their applications
Ciardelli et al. Blends of poly-(ε-caprolactone) and polysaccharides in tissue engineering applications
KR101684790B1 (ko) 비표면적이 다른 이중층 구조를 가지는 경조직 재생용 다공성 멤브레인 및 그 제조방법
Zamani et al. Recent advances in cell electrospining of natural and synthetic nanofibers for regenerative medicine
CN102277737A (zh) 聚己内酯/天然高分子复合多孔支架的制备方法及应用
KR100621569B1 (ko) 조직 재생을 유도하기 위한 생체 모방형태의 나노섬유와마이크로 섬유의 복합지지체 및 그의 제조방법
EP3658197B1 (fr) Nanofibres et membrane électrofilées
AU2021204269A1 (en) Nanofiber structures and methods of synthesis and use thereof
AU2018286644B2 (en) Scaffolds for cell culture and tissue regeneration
de Lima et al. Electrospinning of hydrogels for biomedical applications
Preethi et al. Biomedical applications of natural polymer based nanofibrous scaffolds
Mtibe et al. Recent insight into the biomedical applications of polybutylene succinate and polybutylene succinate-based materials
KR101616345B1 (ko) 나노섬유 및 나노입자를 포함하는 인공피부 및 충전제용 복합지지체, 및 이의 제조방법
Singh et al. Chitin, chitosan, and silk fibroin electrospun nanofibrous scaffolds: a prospective approach for regenerative medicine
WO2017116355A1 (fr) Échafaudage tissulaire à biocompatibilité et propriétés mécaniques améliorées et son procédé de fabrication
KR100464930B1 (ko) 조직재생 유도용 차폐막 및 그의 제조방법
Fan et al. Fabrication and characterization of biopolymer fibers for 3D oriented microvascular structures
El-Sherbiny et al. Eco-friendly electrospun polymeric nanofibers-based nanocomposites for wound healing and tissue engineering
Bafande et al. Features and methods of making nanofibers by electrospinning, phase separation and self-assembly
Bossard et al. Biomaterials from chitosan processed by electrospinning
Sudha et al. Perspectives of chitin-and chitosan-based scaffolds dressing in regenerative medicine
Naghibzadeh Nanofibers for Skin Regeneration.
Hakamada et al. Electrospun poly (γ-benzyl-L-glutamate) and its alkali-treated meshes: Their water wettability and cell-adhesion potential

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16829006

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16829006

Country of ref document: EP

Kind code of ref document: A1